Incidence and risk factors of tuberculosis in patients with human immunodefciency virus infection

Journal of Korean Medical Science

Volumn 28, Issue 3, 2013, Pages 374-377

  Hwang, Jeong Hwan ^a   Choe, Pyoeng Gyun ^a   Kim, Nak Hyun ^a   Bang, Ji Hwan ^a   Song, Kyoung Ho ^a   Park, Wan Beom ^a   Kim, Eu Suk ^a   Park, Sang Won ^a   Kim, Hong Bin ^a   Kim, Nam Joong ^a   Oh, Myoung don ^a   Choe, Kang Won ^a  

^a Seoul National University   (South Korea)

Author keywords

HIV; Incidence; Risk factors; Tuberculosis

Indexed keywords

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; RISK FACTOR; TUBERCULOSIS;

HIV; INCIDENCE; RISK FACTORS; TUBERCULOSIS;

ADULT; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TUBERCULOSIS;

EID: 84875768428     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2013.28.3.374     Document Type: Article

References (21)

1. Oh MD, Park SW, Kim HB, Kim US, Kim NJ, Choi HJ, Shin DH, Lee JS, Choe K. Spectrum of opportunistic infections and malignancies in patients with human immunodeficiency virus infection in South Korea. Clin Infect Dis 1999; 29: 1524-8.
2. Havlir DV, Barnes PF. Tuberculosis in patients with human immunode-fciency virus infection. N Engl J Med 1999; 340: 367-73.
3. Bucher HC, Grifth LE, Guyatt GH, Sudre P, Naef M, Sendi P, Battegay M. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-anal-ysis of randomized controlled trials. AIDS 1999; 13: 501-7.
4. Whalen C, Horsburgh CR, Hom D, Lahart C, Simberkof M, Ellner J. Accelerated course of human immunodefciency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151: 129-35.
5. Lee CH, Hwang JY, Oh DK, Kee MK, Oh E, An JW, Kim J, Do H, Kim HJ, Kim SS, et al. Te burden and characteristics of tuberculosis/human im-munodefciency virus (TB/HIV) in South Korea: a study from a population database and a survey. BMC Infect Dis 2010; 10: 66.
6. Shin HS, Kim US, Kim NJ, Oh MD, Choe K. Incidence and risk factors of JKMS tuberculosis in human immunodefciency virus-infected patients in Korea. Korean J Infect Dis 1999; 31: 225-31.
7. Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR. Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. Clin Infect Dis 2009; 49: 1350-7.
8. Kingkaew N, Sangtong B, Amnuaiphon W, Jongpaibulpatana J, Mankatit-tham W, Akksilp S, Sirinak C, Nateniyom S, Burapat C, Kittikraisak W, et al. HIV-associated extrapulmonary tuberculosis in Tailand: epidemiology and risk factors for death. Int J Infect Dis 2009; 13: 722-9.
9. Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors. AIDS 2011; 25: 1505-13.
10. World Health Organization (WHO). Global tuberculosis control: WHO report 2010. Available at http://www.who.int/tb/publications/global_report/2010/en/index.html [accessed on 15 June 2011].
11. Badri M, Wilson D, Wood R. Efect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-64.
12. Miranda A, Morgan M, Jamal L, Laserson K, Barreira D, Silva G, Santos J, Wells C, Paine P, Garrett D. Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS One 2007; 2 e826.
13. Williams BG, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003; 301: 1535-7.
14. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19: 2109-16.
15. Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, Dabis F, Reiss P, Kirk O, Bernasconi E, et al. Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis 2005; 41: 1772-82.
16. Grant AD, Charalambous S, Fielding KL, Day JH, Corbett EL, Chaisson RE, De Cock KM, Hayes RJ, Churchyard GJ. Efect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa a novel randomized incremental recruitment study. JAMA 2005; 293: 2719-25.
17. Golub JE, Pronyk P, Mohapi L, Tsabangu N, Moshabela M, Struthers H, Gray GE, McIntyre JA, Chaisson RE, Martinson NA. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009; 23: 631-6.
18. Sterling TR, Pham PA, Chaisson RE. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin Infect Dis 2010; 50: S223-30.
19. Jones BE, Young SM, Antoniskis D, Davidson PT, Kramer F, Barnes PF. Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodefciency virus infection. Am Rev Respir Dis 1993; 148: 1292-7.
20. Kang YA, Lee HW, Yoon HI, Cho B, Han SK, Shim YS, Yim JJ. Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden countr y. JAMA 2005; 293: 2756-61.
21. Kim JM, Cho GJ, Hong SK, Chang KH, Chung JS, Choi YH, Song YG, Huh A, Yeom JS, Lee KS, et al. Epidemiology and clinical features of HIV infection/AIDS in Korea. Yonsei Med J 2003; 44: 363-70.